We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

CBMX
CombiMatrix Corporation
NasdaqCM
People also watch : NANX ACTG ALTI TINY FEIC
3.15 -0.05 (-1.56%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close 3.20
Open 3.11
Bid 3.08 x 100
Ask 3.12 x 100
52wk Range 2.62 - 24.60
Day's Range 2.98 - 3.18
Volume 207,964
Avg Vol (3m) 180,655
As of 4:00 PM EDT. Market closed.
  • Zacks Small Cap Research last month

    CBMX: Largest Study To-Date Further Supports Superiority of CMA

    While several studies over the last number of years, including the widely cited Reddy et al and Wapner et al studies which have positively influenced reimbursement policy, have all indicated  that chromosomal microarray analysis (CMA) is the preferred genetic testing modality versus karyotyping due to the former's proven greater accuracy, that it provides more substantive clinical information and is able to be used on fresh as well as preserved (i.e.

  • CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q1, 2016 By the Numbers
    Capital Cube 2 months ago

    CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q1, 2016 By the Numbers

    Click here to see latest analysisCombiMatrix Corp. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of CombiMatrix Corp. – Laboratory Corporation of America Holdings, Sequenom, Inc., Quest Diagnostics Incorporated and NeoGenomics, Inc. (LH-US, SQNM-US, DGX-US and NEO-US) that have also reported for this period.HighlightsSummary numbers: […] (Read more...) The post CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q1, 2016 By the Numbers appeared first on CapitalCube.

  • Zacks Small Cap Research 3 months ago

    CBMX: Reimbursement Very Strong, Could Be At Inflection Point

    While CombiPGS (IVF test) volume slipped from 202 in Q4 of last year to 167 (-17%) in the most recent quarter, total PGS revenue was an identical $222k in both of those periods.  That’s because, similar to miscarriage testing, it also experienced a nice jump in average pricing – moving from an average of $1,145 in 2015 (including $1,099 in Q4) to $1,329 in Q1 of this year.  And similar revenue on lower volume but higher pricing should benefit margins due to less processing costs.  And despite the 17% sequential (i.e.

  • Benzinga 3 months ago

    CombiMatrix Gives Up Early Morning Gains Following Announcement Of Strategic Review

    CombiMatrix Corp (NASDAQ: CBMX ), a molecular diagnostics company, announced on Thursday it has begun to explore strategic alternatives, including potential M&A activity and business development opportunities. ...

  • Insider Monkey 3 months ago

    Traders Are Buzzing About These Five Hot Stocks Today

    With crude futures down 2% and all three major indexes in the red, the S&P 500 is now below 2,100 and the Dow Jones index is just 60 points above 18,000. Among the stocks that are doing well today are Crestwood Equity Partners LP (NYSE:CEQP), ServiceNow Inc (NYSE:NOW), CombiMatrix Corp (NASDAQ:CBMX), Raymond James Financial, Inc. (NYSE:RJF), and […]

  • Zacks Small Cap Research 3 months ago

    CBMX: Several Recent Events Could Catalyze Additional Growth

    By Brian Marckx, CFA NASDAQ:CBMX Several Recent Events Could Catalyze Additional Revenue Growth Including; Updated Prenatal Testing Guidelines, Beneficial Revisions to Insurers’ Coverage Policies and Launch ...

  • TheStreet.com 5 months ago

    8 Stocks Under $10 to Trade for Big Gains

    When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

  • Thomson Reuters StreetEvents 5 months ago

    Edited Transcript of CBMX earnings conference call or presentation 17-Feb-16 9:30pm GMT

    Q4 2015 CombiMatrix Corp Earnings Call

  • CombiMatrix Corp. Earnings Analysis: 2015 By the Numbers
    Capital Cube 5 months ago

    CombiMatrix Corp. Earnings Analysis: 2015 By the Numbers

    Click here to see latest analysisCombiMatrix Corp. reports financial results for the year ended December 31, 2015.We analyze the earnings along side the following peers of CombiMatrix Corp. – Quest Diagnostics Incorporated and Laboratory Corporation of America Holdings (DGX-US and LH-US) that have also reported for this period.HighlightsGross margins widened from 44.72% to 46.03% compared […] (Read more...) The post CombiMatrix Corp. Earnings Analysis: 2015 By the Numbers appeared first on CapitalCube.

  • Zacks Small Cap Research 5 months ago

    CBMX: Solid Q4, PGS and Miscarriage On A Tear

    By Brian Marckx, CFA NASDAQ:CBMX Q4:  Miscarriage and PGS Drive 21% Revenue Growth  CombiMatrix (NASDAQ:CBMX) reported financial results for the fourth quarter ending December 31st.  Diagnostic services ...